(PRAX) Praxis Precision Medicines - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 8.080m USD | Total Return: 750.8% in 12m

Stock Ulixacaltamide, Vormatrigine, Relutrigine, Elsunersen, PRAX-020
Total Rating 44
Risk 67
Buy Signal 0.74
Biotechnology +0.2
Biotechnology +1.0
Market Cap: 8,080m
Avg Trading Vol: 124M USD
ATR: 6.54%
Peers RS (IBD): 98.3
Risk 5d forecast
Volatility101%
Rel. Tail Risk-13.3%
Reward TTM
Sharpe Ratio1.60
Alpha709.96
Character TTM
Beta1.358
Beta Downside1.796
Drawdowns 3y
Max DD68.64%
CAGR/Max DD2.89
EPS (Earnings per Share) EPS (Earnings per Share) of PRAX over the last years for every Quarter: "2021-03": -0.71, "2021-06": -0.88, "2021-09": -1, "2021-12": -1.3, "2022-03": -1.51, "2022-06": -1.32, "2022-09": -0.96, "2022-12": -0.87, "2023-03": -0.71, "2023-06": -0.49, "2023-09": -0.18, "2023-12": -2.97, "2024-03": -2.84, "2024-06": -1.74, "2024-09": -2.75, "2024-12": -2.94, "2025-03": -3.29, "2025-06": -3.31, "2025-09": -3.36, "2025-12": -3.5,
EPS CAGR: -45.69%
EPS Trend: -72.5%
Last SUE: -0.22
Qual. Beats: 0
Revenue Revenue of PRAX over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0.683, 2023-06: 0.781, 2023-09: 0.468, 2023-12: 0.515, 2024-03: 0.431, 2024-06: 0.357, 2024-09: 0.302, 2024-12: 7.463, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0,
Rev. CAGR: 0.00%
Rev. Trend: 12.5%
Last SUE: -0.09
Qual. Beats: 0
Risks
Technicals: choppy
Description: PRAX Praxis Precision Medicines February 27, 2026

Praxis Precision Medicines (NASDAQ: PRAX) is a Boston-based, clinical-stage biotech focused on central nervous system disorders driven by neuronal excitation-inhibition imbalance. Its two discovery platforms-Cerebrum (small-molecule CNS therapeutics) and Solidus (antisense oligonucleotides)-support a pipeline that includes Ulixacaltamide (Phase 3 for essential tremor), Vormatrigine (focal-onset epilepsy), Relutrigine (developmental epileptic encephalopathies), and several ASO candidates targeting rare genetic epilepsies such as SCN2A-DEE and SYNGAP1 loss-of-function.

Recent financial disclosures show PRAX holding roughly $150 million in cash and marketable securities, giving it a runway of about 18 months at its current burn rate of $12 million per quarter. The company recently received a $30 million upfront payment from its research collaboration with Ionis Pharmaceuticals, and its Phase 3 Ulixacaltamide trial reported statistically significant improvement in tremor scores versus placebo in the interim analysis released in January 2024.

The CNS biotech sector is benefiting from an estimated 8 % CAGR through 2028, driven by aging demographics and increasing demand for disease-modifying therapies. For a deeper look, check out ValueRay’s analysis of PRAX.

Headlines to Watch Out For
  • FDA approval of ulixacaltamide for essential tremor
  • Clinical trial results for relutrigine impact stock
  • Partnership with Ionis Pharmaceuticals drives pipeline
  • Funding for CNS disorder research affects development
  • Regulatory hurdles for new drug candidates
Piotroski VR‑10 (Strict, 0-10) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.27 > 0.02 and ΔFCF/TA 0.61 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.27 > 3% & CFO -249.4m > Net Income -303.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 10.22 > 1.5 & < 3
Outstanding Shares: last quarter (22.5m) vs 12m ago 12.64% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 1.77%; Δ -1.77% > 0%)
Interest Coverage Ratio: -30.24 > 6 (EBITDA TTM -313.5m / Interest Expense TTM -10.4m)
Altman Z'' -15.00
A: 0.59 (Total Current Assets 610.9m - Total Current Liabilities 59.8m) / Total Assets 937.9m
B: -1.22 (Retained Earnings -1.14b / Total Assets 937.9m)
C: -0.44 (EBIT TTM -313.6m / Avg Total Assets 710.5m)
D: -19.07 (Book Value of Equity -1.14b / Total Liabilities 59.8m)
Altman-Z'' Score: -23.10 = D
Beneish M
DSRI: none (Receivables none/none, Revenue 0.0/8.55m)
GMI: 1.00 (fallback, negative margins)
AQI: 2.18 (AQ_t 0.35 / AQ_t-1 0.16)
SGI: none (Revenue 0.0 / 8.55m)
TATA: -0.06 (NI -303.3m - CFO -249.4m) / TA 937.9m)
Beneish M-Score: cannot calculate (missing components)
What is the price of PRAX shares? As of April 01, 2026, the stock is trading at USD 322.19 with a total of 634,430 shares traded.
Over the past week, the price has changed by +9.35%, over one month by -2.54%, over three months by +9.31% and over the past year by +750.78%.
Is PRAX a buy, sell or hold? Praxis Precision Medicines has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy PRAX.
  • StrongBuy: 8
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • StrongSell: 1
What are the forecasts/targets for the PRAX price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 617.6 91.7%
Analysts Target Price 617.6 91.7%
PRAX Fundamental Data Overview March 29, 2026
P/S = 953.14
P/B = 9.4612
Revenue TTM = 0.0 USD
EBIT TTM = -313.6m USD
EBITDA TTM = -313.5m USD
Long Term Debt = 110k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 110k USD (from shortTermDebt, last quarter)
Debt = 110k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -357.2m USD (from netDebt column, last quarter)
Enterprise Value = 7.48b USD (8.08b + Debt 110k - CCE 599.3m)
Interest Coverage Ratio = -30.24 (Ebit TTM -313.6m / Interest Expense TTM -10.4m)
EV/FCF = -29.98x (Enterprise Value 7.48b / FCF TTM -249.5m)
FCF Yield = -3.34% (FCF TTM -249.5m / Enterprise Value 7.48b)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 189.6m) / Revenue TTM)
 Tobins Q-Ratio = 7.98 (Enterprise Value 7.48b / Total Assets 937.9m)
 Interest Expense / Debt = 96.36% (Interest Expense 106k / Debt 110k)
 Taxrate = 21.0% (US default 21%)
NOPAT = -247.8m (EBIT -313.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.22 (Total Current Assets 610.9m / Total Current Liabilities 59.8m)
Debt / Equity = 0.00 (Debt 110k / totalStockholderEquity, last quarter 878.1m)
 Debt / EBITDA = 1.14 (negative EBITDA) (Net Debt -357.2m / EBITDA -313.5m)
 Debt / FCF = 1.43 (negative FCF - burning cash) (Net Debt -357.2m / FCF TTM -249.5m)
 Total Stockholder Equity = 516.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.68% (Net Income -303.3m / Total Assets 937.9m)
RoE = -58.74% (Net Income TTM -303.3m / Total Stockholder Equity 516.3m)
RoCE = -60.74% (EBIT -313.6m / Capital Employed (Equity 516.3m + L.T.Debt 110k))
 RoIC = -47.99% (negative operating profit) (NOPAT -247.8m / Invested Capital 516.3m)
 WACC = 10.76% (E(8.08b)/V(8.08b) * Re(10.76%) + (debt cost/tax rate unavailable))
Discount Rate = 10.76% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 57.60%
 [DCF] Fair Price = unknown (Cash Flow -249.5m)
 EPS Correlation: -72.46 | EPS CAGR: -45.69% | SUE: -0.22 | # QB: 0
Revenue Correlation: 12.49 | Revenue CAGR: 0.0% | SUE: -0.09 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-3.79 | Chg7d=+0.000 | Chg30d=-0.089 | Revisions Net=-3 | Analysts=12
EPS current Year (2026-12-31): EPS=-15.22 | Chg7d=+0.000 | Chg30d=-2.408 | Revisions Net=-6 | Growth EPS=-12.9% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-8.65 | Chg7d=+0.000 | Chg30d=-3.771 | Revisions Net=-7 | Growth EPS=+43.2% | Growth Revenue=+4602.6%
[Analyst] Revisions Ratio: -0.60 (1 Up / 4 Down within 30d for Next Quarter)
Additional Sources for PRAX Stock Fund Manager Positions: Dataroma · Stockcircle